BioNTech: 'No evidence' that adapting vaccine to variants is necessary

BioNTech said Monday there is currently "no evidence" to support the need to adapt the company's coronavirus vaccine, developed with Pfizer, to be more effective against emerging variants. Why it matters: Some health experts fear that contagious new variants could be more resistant against COVID-19 vaccines, prolonging the pandemic for years to come.